Cardio Diagnostics Holdings, Inc. Logo

Cardio Diagnostics Holdings, Inc.

CDIO

(1.8)
Stock Price

0,55 USD

-259.06% ROA

-308.99% ROE

-0.55x PER

Market Cap.

5.085.376,00 USD

28.31% DER

0% Yield

-22415.27% NPM

Cardio Diagnostics Holdings, Inc. Stock Analysis

Cardio Diagnostics Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cardio Diagnostics Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.71x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

Negative ROE (-173.6%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-79.12%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Cardio Diagnostics Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cardio Diagnostics Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Cardio Diagnostics Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cardio Diagnostics Holdings, Inc. Revenue
Year Revenue Growth
2020 0
2021 901 100%
2022 950 5.16%
2023 40.120 97.63%
2023 17.065 -135.1%
2024 31.480 45.79%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cardio Diagnostics Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2020 1.500
2021 31.468 95.23%
2022 40.448 22.2%
2023 154.832 73.88%
2023 145.182 -6.65%
2024 29.120 -398.56%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cardio Diagnostics Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2020 591.521
2021 470.563 -25.7%
2022 4.400.253 89.31%
2023 5.506.576 20.09%
2023 6.936.646 20.62%
2024 4.881.908 -42.09%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cardio Diagnostics Holdings, Inc. EBITDA
Year EBITDA Growth
2020 -598.497
2021 -604.448 0.98%
2022 -4.419.917 86.32%
2023 -5.614.732 21.28%
2023 -7.130.840 21.26%
2024 -4.966.680 -43.57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cardio Diagnostics Holdings, Inc. Gross Profit
Year Gross Profit Growth
2020 0
2021 901 100%
2022 -15.050 105.99%
2023 40.120 137.51%
2023 -94.555 142.43%
2024 -131.664 28.18%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cardio Diagnostics Holdings, Inc. Net Profit
Year Net Profit Growth
2020 -605.164
2021 -620.448 2.46%
2022 -4.660.985 86.69%
2023 -7.729.528 39.7%
2023 -8.376.834 7.73%
2024 -5.151.980 -62.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cardio Diagnostics Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2020 0
2021 -1 0%
2022 -2 100%
2023 -1 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cardio Diagnostics Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
2020 -4.051
2021 -699.320 99.42%
2022 -5.167.122 86.47%
2023 -1.131.669 -356.59%
2023 -6.445.114 82.44%
2024 -1.302.991 -394.64%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cardio Diagnostics Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
2020 25.859
2021 -585.291 104.42%
2022 -5.090.968 88.5%
2023 -1.044.599 -387.36%
2023 -5.672.175 81.58%
2024 -1.233.050 -360.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cardio Diagnostics Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
2020 29.910
2021 114.029 73.77%
2022 76.154 -49.73%
2023 87.070 12.54%
2023 772.939 88.74%
2024 69.941 -1005.13%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cardio Diagnostics Holdings, Inc. Equity
Year Equity Growth
2020 60.365
2021 1.068.109 94.35%
2022 4.301.708 75.17%
2023 2.287.731 -88.03%
2023 2.958.124 22.66%
2024 3.074.236 3.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cardio Diagnostics Holdings, Inc. Assets
Year Assets Growth
2020 446.375
2021 1.101.994 59.49%
2022 6.249.478 82.37%
2023 5.963.307 -4.8%
2023 4.462.365 -33.64%
2024 3.996.765 -11.65%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cardio Diagnostics Holdings, Inc. Liabilities
Year Liabilities Growth
2020 386.010
2021 33.885 -1039.18%
2022 1.947.770 98.26%
2023 3.675.576 47.01%
2023 1.504.241 -144.35%
2024 922.529 -63.06%

Cardio Diagnostics Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.39
Price to Earning Ratio
-0.55x
Price To Sales Ratio
129.93x
POCF Ratio
-0.91
PFCF Ratio
-0.84
Price to Book Ratio
1.56
EV to Sales
118.7
EV Over EBITDA
-0.56
EV to Operating CashFlow
-0.88
EV to FreeCashFlow
-0.77
Earnings Yield
-1.83
FreeCashFlow Yield
-1.19
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.09
Graham NetNet
0.02

Income Statement Metrics

Net Income per Share
-0.39
Income Quality
0.46
ROE
-3.09
Return On Assets
-2.19
Return On Capital Employed
-2.33
Net Income per EBT
1
EBT Per Ebit
1.04
Ebit per Revenue
-215.31
Effective Tax Rate
-0.07

Margins

Sales, General, & Administrative to Revenue
209.84
Research & Developement to Revenue
1.64
Stock Based Compensation to Revenue
96.96
Gross Profit Margin
-2.86
Operating Profit Margin
-215.31
Pretax Profit Margin
-224.15
Net Profit Margin
-224.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.23
Free CashFlow per Share
-0.27
Capex to Operating CashFlow
-0.15
Capex to Revenue
20.74
Capex to Depreciation
5.44
Return on Invested Capital
-2.28
Return on Tangible Assets
-2.59
Days Sales Outstanding
70.13
Days Payables Outstanding
125.72
Days of Inventory on Hand
0
Receivables Turnover
5.2
Payables Turnover
2.9
Inventory Turnover
0
Capex per Share
0.04

Balance Sheet

Cash per Share
0,06
Book Value per Share
0,14
Tangible Book Value per Share
0.11
Shareholders Equity per Share
0.14
Interest Debt per Share
0.07
Debt to Equity
0.28
Debt to Assets
0.22
Net Debt to EBITDA
0.05
Current Ratio
5.69
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
3607819
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.15
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cardio Diagnostics Holdings, Inc. Dividends
Year Dividends Growth

Cardio Diagnostics Holdings, Inc. Profile

About Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

CEO
Dr. Meeshanthini V. Dogan Ph.D
Employee
7
Address
400 N Aberdeen St
Chicago, 60642

Cardio Diagnostics Holdings, Inc. Executives & BODs

Cardio Diagnostics Holdings, Inc. Executives & BODs
# Name Age
1 Dr. Robert A. Philibert M.D., Ph.D.
Co-Founder, Chief Medical Officer & Director
70
2 Ms. Elisa Michael Luqman Esq., J.D., M.B.A.
Chief Financial Officer
70
3 Ms. Khullani Abdullahi J.D.
Vice President of Revenue & Strategy
70
4 Mr. Timur Dogan Ph.D.
Chief Technology Officer
70
5 Dr. Meeshanthini V. Dogan Ph.D.
Co-Founder, Chief Executive Officer & Director
70

Cardio Diagnostics Holdings, Inc. Competitors